Efficacy and Tolerability of Enstilar® in Daily Practice

• Status: Completed
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. In addition the profiles of patients prescribed Enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. The study will be conducted in about 100 dermatology clinics all over Germany,

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LEO Pharma
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Calcipotriene; Calcitriol

Criteria

Inclusion Criteria:

• ≥ 18 years of age

• Psoriasis vulgaris

• Lesions on trunk and/or extremities of at least mild severity

• Treatment with Enstilar® planned

• Signed informed consent to participate

Exclusion Criteria:

• Enrolled in any interventional clinical trial

• Ongoing or recent treatment with any systemic psoriasis

• Ongoing or recent treatment with UV-therapy

• Ongoing or previous treatment with Enstilar®

• Psoriasis of scalp only

• Other forms of psoriasis, e.g. erythrodermic or pustular psoriasis

• More than 30% of surface area affected by psoriasis

• Any contraindications or known allergies to Enstilar® or its ingredients

• Incapacitated patients under institutionalized care